Cargando…
The clinical significance of CD44v6 in malignant and benign primary bone tumors
BACKGROUND: The objective of this study was to assess the expression profile of CD44v6, a potential cancer stem cell marker, and its diagnostic and predictive significance in three distinct types of primary bone tumors. METHODS: In this study, we utilized real-time qRT-PCR and immunohistochemistry t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10367246/ https://www.ncbi.nlm.nih.gov/pubmed/37491225 http://dx.doi.org/10.1186/s12891-023-06738-7 |
_version_ | 1785077346227716096 |
---|---|
author | Hosseini, Ameinh Eghtedari, Amir Reza Mirzaei, Alireza Babaheidarian, Pegah Nekoufar, Samira Khademian, Narges Jamshidi, Khodamorad Tavakoli-Yaraki, Masoumeh |
author_facet | Hosseini, Ameinh Eghtedari, Amir Reza Mirzaei, Alireza Babaheidarian, Pegah Nekoufar, Samira Khademian, Narges Jamshidi, Khodamorad Tavakoli-Yaraki, Masoumeh |
author_sort | Hosseini, Ameinh |
collection | PubMed |
description | BACKGROUND: The objective of this study was to assess the expression profile of CD44v6, a potential cancer stem cell marker, and its diagnostic and predictive significance in three distinct types of primary bone tumors. METHODS: In this study, we utilized real-time qRT-PCR and immunohistochemistry to examine the gene and protein levels of CD44v6 in a total of 138 fresh bone tissues. This included 69 tumor tissues comprising osteosarcoma (N = 23), chondrosarcoma (N = 23), and GCT (N = 23), as well as 69 corresponding non-cancerous tumor margins. Furthermore, we investigated the circulating level of CD44v6 by isolating peripheral blood mononuclear cells from 92 blood samples. Among these, 69 samples were obtained from patients diagnosed with primary bone tumors, while the remaining 23 samples were from healthy donors. The primary objectives of our investigation were to assess the correlation between CD44v6 expression levels and clinic-pathological features of the patients, as well as to evaluate the diagnostic and predictive values of CD44v6 in this context. RESULTS: In patients with osteosarcoma and chondrosarcoma tumors, both the gene and protein expression of CD44v6 were found to be significantly higher compared to the GCT group. Furthermore, the circulating level of CD44v6 was notably elevated in patients diagnosed with osteosarcoma and chondrosarcoma in comparison to the GCT group and patients with malignant tumor characteristics. Additionally, we observed a strong correlation between the gene and protein levels of CD44v6 and important tumor indicators such as tumor grade, metastasis, recurrence, and size at the tumor site. CD44v6 shows potential in differentiating patients with bone tumors from both control groups and tumor groups with severe and invasive characteristics from those with non-severe features. Importantly, the expression level of CD44v6 also demonstrated predictive value for determining tumor grade and the likelihood of recurrence. CONCLUSION: CD44v6 is likely to play a role in the development of primary bone tumors and has the potential to serve as a diagnostic biomarker for bone cancer. However, to obtain more accurate and conclusive findings, further mechanistic investigations involving larger population samples are necessary. |
format | Online Article Text |
id | pubmed-10367246 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-103672462023-07-26 The clinical significance of CD44v6 in malignant and benign primary bone tumors Hosseini, Ameinh Eghtedari, Amir Reza Mirzaei, Alireza Babaheidarian, Pegah Nekoufar, Samira Khademian, Narges Jamshidi, Khodamorad Tavakoli-Yaraki, Masoumeh BMC Musculoskelet Disord Research BACKGROUND: The objective of this study was to assess the expression profile of CD44v6, a potential cancer stem cell marker, and its diagnostic and predictive significance in three distinct types of primary bone tumors. METHODS: In this study, we utilized real-time qRT-PCR and immunohistochemistry to examine the gene and protein levels of CD44v6 in a total of 138 fresh bone tissues. This included 69 tumor tissues comprising osteosarcoma (N = 23), chondrosarcoma (N = 23), and GCT (N = 23), as well as 69 corresponding non-cancerous tumor margins. Furthermore, we investigated the circulating level of CD44v6 by isolating peripheral blood mononuclear cells from 92 blood samples. Among these, 69 samples were obtained from patients diagnosed with primary bone tumors, while the remaining 23 samples were from healthy donors. The primary objectives of our investigation were to assess the correlation between CD44v6 expression levels and clinic-pathological features of the patients, as well as to evaluate the diagnostic and predictive values of CD44v6 in this context. RESULTS: In patients with osteosarcoma and chondrosarcoma tumors, both the gene and protein expression of CD44v6 were found to be significantly higher compared to the GCT group. Furthermore, the circulating level of CD44v6 was notably elevated in patients diagnosed with osteosarcoma and chondrosarcoma in comparison to the GCT group and patients with malignant tumor characteristics. Additionally, we observed a strong correlation between the gene and protein levels of CD44v6 and important tumor indicators such as tumor grade, metastasis, recurrence, and size at the tumor site. CD44v6 shows potential in differentiating patients with bone tumors from both control groups and tumor groups with severe and invasive characteristics from those with non-severe features. Importantly, the expression level of CD44v6 also demonstrated predictive value for determining tumor grade and the likelihood of recurrence. CONCLUSION: CD44v6 is likely to play a role in the development of primary bone tumors and has the potential to serve as a diagnostic biomarker for bone cancer. However, to obtain more accurate and conclusive findings, further mechanistic investigations involving larger population samples are necessary. BioMed Central 2023-07-25 /pmc/articles/PMC10367246/ /pubmed/37491225 http://dx.doi.org/10.1186/s12891-023-06738-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Hosseini, Ameinh Eghtedari, Amir Reza Mirzaei, Alireza Babaheidarian, Pegah Nekoufar, Samira Khademian, Narges Jamshidi, Khodamorad Tavakoli-Yaraki, Masoumeh The clinical significance of CD44v6 in malignant and benign primary bone tumors |
title | The clinical significance of CD44v6 in malignant and benign primary bone tumors |
title_full | The clinical significance of CD44v6 in malignant and benign primary bone tumors |
title_fullStr | The clinical significance of CD44v6 in malignant and benign primary bone tumors |
title_full_unstemmed | The clinical significance of CD44v6 in malignant and benign primary bone tumors |
title_short | The clinical significance of CD44v6 in malignant and benign primary bone tumors |
title_sort | clinical significance of cd44v6 in malignant and benign primary bone tumors |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10367246/ https://www.ncbi.nlm.nih.gov/pubmed/37491225 http://dx.doi.org/10.1186/s12891-023-06738-7 |
work_keys_str_mv | AT hosseiniameinh theclinicalsignificanceofcd44v6inmalignantandbenignprimarybonetumors AT eghtedariamirreza theclinicalsignificanceofcd44v6inmalignantandbenignprimarybonetumors AT mirzaeialireza theclinicalsignificanceofcd44v6inmalignantandbenignprimarybonetumors AT babaheidarianpegah theclinicalsignificanceofcd44v6inmalignantandbenignprimarybonetumors AT nekoufarsamira theclinicalsignificanceofcd44v6inmalignantandbenignprimarybonetumors AT khademiannarges theclinicalsignificanceofcd44v6inmalignantandbenignprimarybonetumors AT jamshidikhodamorad theclinicalsignificanceofcd44v6inmalignantandbenignprimarybonetumors AT tavakoliyarakimasoumeh theclinicalsignificanceofcd44v6inmalignantandbenignprimarybonetumors AT hosseiniameinh clinicalsignificanceofcd44v6inmalignantandbenignprimarybonetumors AT eghtedariamirreza clinicalsignificanceofcd44v6inmalignantandbenignprimarybonetumors AT mirzaeialireza clinicalsignificanceofcd44v6inmalignantandbenignprimarybonetumors AT babaheidarianpegah clinicalsignificanceofcd44v6inmalignantandbenignprimarybonetumors AT nekoufarsamira clinicalsignificanceofcd44v6inmalignantandbenignprimarybonetumors AT khademiannarges clinicalsignificanceofcd44v6inmalignantandbenignprimarybonetumors AT jamshidikhodamorad clinicalsignificanceofcd44v6inmalignantandbenignprimarybonetumors AT tavakoliyarakimasoumeh clinicalsignificanceofcd44v6inmalignantandbenignprimarybonetumors |